Cargando…
The Oncogenic Signaling Disruptor, NDRG1: Molecular and Cellular Mechanisms of Activity
NDRG1 is an oncogenic signaling disruptor that plays a key role in multiple cancers, including aggressive pancreatic tumors. Recent studies have indicated a role for NDRG1 in the inhibition of multiple tyrosine kinases, including EGFR, c-Met, HER2 and HER3, etc. The mechanism of activity of NDRG1 re...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8465210/ https://www.ncbi.nlm.nih.gov/pubmed/34572031 http://dx.doi.org/10.3390/cells10092382 |
_version_ | 1784572813522239488 |
---|---|
author | Chekmarev, Jason Azad, Mahan Gholam Richardson, Des R. |
author_facet | Chekmarev, Jason Azad, Mahan Gholam Richardson, Des R. |
author_sort | Chekmarev, Jason |
collection | PubMed |
description | NDRG1 is an oncogenic signaling disruptor that plays a key role in multiple cancers, including aggressive pancreatic tumors. Recent studies have indicated a role for NDRG1 in the inhibition of multiple tyrosine kinases, including EGFR, c-Met, HER2 and HER3, etc. The mechanism of activity of NDRG1 remains unclear, but to impart some of its functions, NDRG1 binds directly to key effector molecules that play roles in tumor suppression, e.g., MIG6. More recent studies indicate that NDRG1s-inducing drugs, such as novel di-2-pyridylketone thiosemicarbazones, not only inhibit tumor growth and metastasis but also fibrous desmoplasia, which leads to chemotherapeutic resistance. The Casitas B-lineage lymphoma (c-Cbl) protein may be regulated by NDRG1, and is a crucial E3 ligase that regulates various protein tyrosine and receptor tyrosine kinases, primarily via ubiquitination. The c-Cbl protein can act as a tumor suppressor by promoting the degradation of receptor tyrosine kinases. In contrast, c-Cbl can also promote tumor development by acting as a docking protein to mediate the oncogenic c-Met/Crk/JNK and PI3K/AKT pathways. This review hypothesizes that NDRG1 could inhibit the oncogenic function of c-Cbl, which may be another mechanism of its tumor-suppressive effects. |
format | Online Article Text |
id | pubmed-8465210 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-84652102021-09-27 The Oncogenic Signaling Disruptor, NDRG1: Molecular and Cellular Mechanisms of Activity Chekmarev, Jason Azad, Mahan Gholam Richardson, Des R. Cells Review NDRG1 is an oncogenic signaling disruptor that plays a key role in multiple cancers, including aggressive pancreatic tumors. Recent studies have indicated a role for NDRG1 in the inhibition of multiple tyrosine kinases, including EGFR, c-Met, HER2 and HER3, etc. The mechanism of activity of NDRG1 remains unclear, but to impart some of its functions, NDRG1 binds directly to key effector molecules that play roles in tumor suppression, e.g., MIG6. More recent studies indicate that NDRG1s-inducing drugs, such as novel di-2-pyridylketone thiosemicarbazones, not only inhibit tumor growth and metastasis but also fibrous desmoplasia, which leads to chemotherapeutic resistance. The Casitas B-lineage lymphoma (c-Cbl) protein may be regulated by NDRG1, and is a crucial E3 ligase that regulates various protein tyrosine and receptor tyrosine kinases, primarily via ubiquitination. The c-Cbl protein can act as a tumor suppressor by promoting the degradation of receptor tyrosine kinases. In contrast, c-Cbl can also promote tumor development by acting as a docking protein to mediate the oncogenic c-Met/Crk/JNK and PI3K/AKT pathways. This review hypothesizes that NDRG1 could inhibit the oncogenic function of c-Cbl, which may be another mechanism of its tumor-suppressive effects. MDPI 2021-09-10 /pmc/articles/PMC8465210/ /pubmed/34572031 http://dx.doi.org/10.3390/cells10092382 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Chekmarev, Jason Azad, Mahan Gholam Richardson, Des R. The Oncogenic Signaling Disruptor, NDRG1: Molecular and Cellular Mechanisms of Activity |
title | The Oncogenic Signaling Disruptor, NDRG1: Molecular and Cellular Mechanisms of Activity |
title_full | The Oncogenic Signaling Disruptor, NDRG1: Molecular and Cellular Mechanisms of Activity |
title_fullStr | The Oncogenic Signaling Disruptor, NDRG1: Molecular and Cellular Mechanisms of Activity |
title_full_unstemmed | The Oncogenic Signaling Disruptor, NDRG1: Molecular and Cellular Mechanisms of Activity |
title_short | The Oncogenic Signaling Disruptor, NDRG1: Molecular and Cellular Mechanisms of Activity |
title_sort | oncogenic signaling disruptor, ndrg1: molecular and cellular mechanisms of activity |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8465210/ https://www.ncbi.nlm.nih.gov/pubmed/34572031 http://dx.doi.org/10.3390/cells10092382 |
work_keys_str_mv | AT chekmarevjason theoncogenicsignalingdisruptorndrg1molecularandcellularmechanismsofactivity AT azadmahangholam theoncogenicsignalingdisruptorndrg1molecularandcellularmechanismsofactivity AT richardsondesr theoncogenicsignalingdisruptorndrg1molecularandcellularmechanismsofactivity AT chekmarevjason oncogenicsignalingdisruptorndrg1molecularandcellularmechanismsofactivity AT azadmahangholam oncogenicsignalingdisruptorndrg1molecularandcellularmechanismsofactivity AT richardsondesr oncogenicsignalingdisruptorndrg1molecularandcellularmechanismsofactivity |